Table 3.
Inter-cluster comparison of clinical characteristics between the symptom-based clusters
Inter cluster comparison between clinical variables. Overall significance between groups depicted with p<0.05 considered significant.
| Cluster A (n=6) | Cluster B (n=28) | Cluster C (n= 30) | Cluster D (n=10) | Cluster E (n=23) | p | |
|---|---|---|---|---|---|---|
| Age in years (mean ± SEM) | 47 ± 6 | 48.5 ± 3 | 52.7 ± 3 | 47.2 ± 4 | 54.6 ± 3 | 0.40 |
| Gender (Women, %) | 4 (67) | 11 (39) | 8 (27) | 3 (30) | 6 (26) | 0.32 |
| Vitamin D3 ng/ml (mean) | 23.4 ± 7 | 30.7 ± 4 | 35.8 ± 4 | 27 ± 6 | 38.3 ± 5 | 0.33 |
| Eosinophil cells/mm3 (Mean) | 472 ± 195 | 835 ± 87 | 601 ± 81 | 507 ± 145 | 607 ± 100 | 0.15 |
| Lund McKay Score CT Total, pre-surgical (mean ± SEM) | 11.6 ± 2 | 14.5 ± 1 | 15.8 ± 1 | 12.4 ± 1 | 12.8 ± 1 | 0.02 |
| Total pre-surgical SNOT-22 score | 90.8 ± 3 | 62 ± 1 | 40.3 ± 1 | 37.7 ± 2 | 16.4 ± 2 | < 0.001 |
| Symptom cluster affinity | Both | Sinonasal | Sinonasal | Non Sinonasal | Sinonasal | |
| History of ASA sensitivity (%) | 3 (50) | 11 (39) | 7 (23) | 0 (0) | 1 (4) | 0.006 |
| Proportion of patients with h/o ASA sensitivity that were challenged and were positive | 1 of 1 (100%) | 6 of 8 (75%) | 4 of 5 (80%) | - | 0 | |
| Nasal polyposis | 4 (67) | 27 (96) | 24 (80) | 10 (100) | 17 (74) | 0.06 |
| Asthma (%) | 3 (50) | 21 (75) | 16 (53) | 6 (60) | 13 (56) | 0.47 |
| Atopy (%)* | 2 (50) | 12 (54) | 14 (56) | 8 (100) | 11 (61) | 0.20 |
| Any systemic corticosteroid use (%)** | 2 (33) | 1 (4) | 1 (3) | 3 (30) | 2 (8) | 0.02 |
| Post-surgical followup | ||||||
| Total post-surgical SNOT-22 score (Visit 1) | 44 ± 7 | 21.3 ± 3 | 24 ± 3 | 16.8 ± 5 | 12.9 ± 4 | 0.006 |
| Total post-surgical SNOT-22 score (Visit 2) | 55.6 ± 9 | 20.6 ± 4 | 27 ± 4 | 9.5 ± 6 | 13.6 ± 4 | <0.001 |
*
total N for which skin testing was available for cluster A=4, B=22, C=25, D=8 and E=18
**
Injection triamcinolone within 2 months or oral prednisone within1 month of assessment